Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G1B | P04054 | 1/20 | 0.56 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 8/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | S1PR2 | O95136 | 4/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8285701 | 0.93 | PLA2G1B (0.55) | PLA2G1BPLA2G2ASIGMAR1NPSR1CACNA2D1 | |
| SCHEMBL30601205 | 0.93 | PLA2G1B (0.61) | PLA2G1BPLA2G2ASIGMAR1NPSR1CACNA2D1 | |
| SCHEMBL1147021 | 0.92 | PLA2G1B (0.59) | PLA2G1BPLA2G2ASIGMAR1NPSR1CACNA2D1 | |
| Hydrochloric Acid SCHEMBL3877978 | 0.91 | PLA2G1B (0.53) | PLA2G1BPLA2G2ASIGMAR1NPSR1CACNA2D1 | |
| SCHEMBL22442865 | 0.83 | PLA2G1B (0.55) | PLA2G1BPLA2G2ASIGMAR1CACNA2D1ALDH1A1 | |
| SCHEMBL3856955 | 0.82 | OPRM1 (0.50) | PLA2G1BPLA2G2ASIGMAR1NPSR1CACNA2D1 | |
| SCHEMBL417108 | 0.82 | OPRM1 (0.50) | PLA2G1BPLA2G2ASIGMAR1NPSR1CACNA2D1 | |
| SCHEMBL29881540 | 0.82 | OPRM1 (0.50) | PLA2G1BPLA2G2ASIGMAR1NPSR1CACNA2D1 | |
| SCHEMBL3856709 | 0.82 | OPRM1 (0.50) | PLA2G1BPLA2G2ASIGMAR1NPSR1CACNA2D1 | |
| SCHEMBL20828858 | 0.80 | PLA2G1B (0.42) | PLA2G1BPLA2G2ASIGMAR1NPSR1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110045100-A1 | Antimalarial Quinolines and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2011-02-24 | — | — | US | disclosed |
| WO-2009148659-A2 | ANTIMALARIAL QUINOLINES AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045100-A1 | Antimalarial Quinolines and Methods of Use Thereof | NQO2, QTRT1, QTRT2 | PLA2G1B 1379/4885PLA2G2A 1872/4885SIGMAR1 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.